Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Vertex Stock Outperforming the Dow?

With a market cap of $122.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a leading biotechnology company focused on discovering, developing, and commercializing transformative medicines for serious diseases, particularly in areas of high unmet medical need. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex is best known for building the first and dominant class of therapies that treat the underlying cause of cystic fibrosis (CF), establishing a durable global franchise with blockbuster drugs such as Trikafta/Kaftrio.

Companies valued at $10 billion or more are generally considered "large-cap" stocks, and Vertex fits this criterion perfectly, exceeding the mark. 

Fundamentals

See More
  • Market Capitalization, $K 121,969,344
  • Shares Outstanding, K 254,034
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,173 M
  • EBITDA $ 4,383 M
  • 60-Month Beta 0.30
  • Price/Sales 10.22
  • Price/Cash Flow 27.73
  • Price/Book 6.63

Options Overview Details

View History
  • Implied Volatility 41.30% (+0.24%)
  • Historical Volatility 30.56%
  • IV Percentile 97%
  • IV Rank 76.55%
  • IV High 47.19% on 04/08/25
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 7) 21.42 (4.46%)
  • Put/Call Vol Ratio 0.71
  • Today's Volume 2,732
  • Volume Avg (30-Day) 4,888
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 49,341
  • Open Int (30-Day) 41,928
  • Expected Range 458.71 to 501.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.91
  • Number of Estimates 7
  • High Estimate 4.37
  • Low Estimate 3.51
  • Prior Year 3.55
  • Growth Rate Est. (year over year) +10.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
454.40 +5.66%
on 02/11/26
503.88 -4.71%
on 02/13/26
+3.29 (+0.69%)
since 01/26/26
3-Month
423.45 +13.38%
on 12/01/25
503.88 -4.71%
on 02/13/26
+47.96 (+11.10%)
since 11/26/25
52-Week
362.50 +32.45%
on 08/11/25
519.68 -7.61%
on 03/14/25
+1.03 (+0.21%)
since 02/26/25

Most Recent Stories

More News
Is Vertex Stock Outperforming the Dow?

Despite underperforming the Dow Jones Industrial Average over the past year, Vertex continues to earn moderate bullish support from analysts.

VRTX : 480.13 (-0.60%)
$DOWI : 49,499.20 (+0.03%)
BIIB : 188.02 (-1.42%)
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

NFLX : 84.59 (+2.29%)
VRTX : 480.13 (-0.60%)
GILD : 143.77 (-2.28%)
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Get context for CRISPR Therapeutics’ Q4 results: CASGEVY launch economics, cash runway, pipeline upside, and the technical level investors should watch.

CRSP : 61.74 (+11.85%)
MS : 177.49 (+2.16%)
VRTX : 480.13 (-0.60%)
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call

VRTX : 480.13 (-0.60%)
1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down

1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down

SOLV : 76.94 (+2.48%)
VRTX : 480.13 (-0.60%)
VMC : 308.99 (+1.13%)
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen’s 46 th Annual Health Care Conference. Reshma Kewalramani, President and...

VRTX : 480.13 (-0.60%)
Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Vertex Pharmaceuticals’ stock has lagged behind the broader market over the past year, but analysts remain moderately bullish about its prospects.

XLV : 157.42 (-0.26%)
$SPX : 6,908.86 (-0.54%)
VRTX : 480.13 (-0.60%)
Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know

Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know

MOH : 146.36 (+0.56%)
VRTX : 480.13 (-0.60%)
IART : 11.33 (-2.24%)
BAX : 20.36 (-1.78%)
MRNA : 51.71 (+0.66%)
VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase

VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase

VRTX : 480.13 (-0.60%)
Vertex: Q4 Earnings Snapshot

Vertex: Q4 Earnings Snapshot

VRTX : 480.13 (-0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 493.35
2nd Resistance Point 488.49
1st Resistance Point 484.31
Last Price 480.13
1st Support Level 475.27
2nd Support Level 470.41
3rd Support Level 466.23

See More

52-Week High 519.68
Last Price 480.13
Fibonacci 61.8% 459.64
Fibonacci 50% 441.09
Fibonacci 38.2% 422.54
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar